US Patent

US9308284 — Formulations of fluorinated stilbene suitable for PET imaging

Formulation · Assigned to Piramal Imaging SA · Expires 2032-07-14 · 6y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of a fluorinated stilbene suitable for PET imaging that can be administered intravenously.

USPTO Abstract

The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.

Drugs covered by this patent

Patent Metadata

Patent number
US9308284
Jurisdiction
US
Classification
Formulation
Expires
2032-07-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Piramal Imaging SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.